Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Arch Ventures
Deal Size : $200.0 million
Deal Type : Financing
Tenvie Therapeutics Launches With $200M to Develop Small Molecule Therapies
Details : The financing is intended to support the development of the company's pipeline, which includes highly CNS-penetrant & peripherally restricted small molecules targeting CNS & cardiometabolic diseases.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 08, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Arch Ventures
Deal Size : $200.0 million
Deal Type : Financing